Download PDF
1 / Pages

Other users also viewed these articles

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance Deanna D. Hill; Jennifer R. Kramer; Kassie R. Chaffin; T. Christopher Mast; Michael N. Robertson; Fasiha Kanwal; Barbara A. Haber;
Ann Hepatol. 2023;28:
Choosing wisely recommendations regarding the top five list of procedures to avoid in the treatment of viral hepatitis: A position statement from the Brazilian Society of Hepatology endorsed by the Latin American Association for the Study of the liver Cristiane A. Villela-Nogueira; Maria Lúcia Gomes Ferraz; Mário Guimarães Pessoa; Francisco José Dutra Souto; Letícia Cancella Nabuco; Henrique Sérgio Moraes Coelho; Ezequiel Ridruejo; Marcelo Silva; Paulo Lisboa Bittencourt; Carlos Eduardo Brandão-Mello;
Ann Hepatol. 2023;28:
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC Federico Piñero; Margarita Anders; Carla Bermudez; Ezequiel Demirdjian; Adriana Varón; Ana Palazzo; Jorge Rodriguez; Oscar Beltrán; Leonardo Gomes da Fonseca; Ezequiel Ridruejo; Pablo Caballini; Norberto Tamagnone; Virginia Reggiardo; Hugo Cheinquer; Alexandre Araujo; Diego Arufe; Juan Ignacio Marín; Natalia Ratusnu; Estela Manero; Daniela Perez; Marina Villa; Federico Orozco; Dolores Murga; Sebastián Marciano; Fernando Bessone; Marcelo Silva; Manuel Mendizabal;
Ann Hepatol. 2023;28: